Ranibizumab for the treatment of degenerative ocular conditions

Magdalini Triantafylla1 Department of Ophthalmology, University General Hospital of Alexandroupolis, School of Medicine, University of Thrace, Alexandroupolis, Greece

Horace F Massa2 Department of Ophthalmology, Geneva University Hospitals, Faculty of Medicine, University of Geneva, Switzerland

Doukas Dardabounis1 Department of Ophthalmology, University General Hospital of Alexandroupolis, School of Medicine, University of Thrace, Alexandroupolis, Greece

Zisis Gatzioufas2 Department of Ophthalmology, Geneva University Hospitals, Faculty of Medicine, University of Geneva, Switzerland

Vassilios Kozobolis1 Department of Ophthalmology, University General Hospital of Alexandroupolis, School of Medicine, University of Thrace, Alexandroupolis, Greece

Konstantinos Ioannakis1 Department of Ophthalmology, University General Hospital of Alexandroupolis, School of Medicine, University of Thrace, Alexandroupolis, Greece

Irfan Perente1 Department of Ophthalmology, University General Hospital of Alexandroupolis, School of Medicine, University of Thrace, Alexandroupolis, Greece;3 Beyoglou Eye Research and Teaching Hospital, Istanbul University, Istanbul, Turkey

Georgios D Panos1 Department of Ophthalmology, University General Hospital of Alexandroupolis, School of Medicine, University of Thrace, Alexandroupolis, Greece;2 Department of Ophthalmology, Geneva University Hospitals, Faculty of Medicine, University of Geneva, SwitzerlandCorrespondence[email protected]

show all

Abstract

Degenerative ocular conditions, such as age-related macular degeneration, diabetic retinopathy, retinal vein occlusions, and myopic degeneration, have become a major public health problem and a leading cause of blindness in developed countries. Anti-vascular endothelial growth factor (VEGF) drugs seem to be an effective and safe treatment for these conditions. Ranibizumab, a humanized monoclonal antibody antigen-binding fragment, which inhibits all biologically active isoforms of VEGF-A, is still the gold standard treatment for the majority of these pathological entities. In this review, we present the results of the most important clinical trials concerning the efficacy and safety of ranibizumab for the treatment of degenerative ocular conditions.

Keywords:

Disclosure

The authors report no conflicts of interest in this work.

Ranibizumab for the treatment of degenerative ocular conditions

Information for

Open access

Opportunities

Help and information

Ranibizumab for the treatment of degenerative ocular conditions

Abstract

Disclosure

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature